Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
GlobeNewswire
· Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment
·..